<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332186</url>
  </required_header>
  <id_info>
    <org_study_id>CV013-025</org_study_id>
    <nct_id>NCT03332186</nct_id>
  </id_info>
  <brief_title>A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function</brief_title>
  <official_title>A Phase 1, Open-Label, Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986231 in Subjects With Varying Degrees of Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate experimental medication BMS-986231 in patients
      with different levels of kidney function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">September 16, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 16, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) derived from plasma concentration</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time 0 extrapolated to infinity [AUC(0-inf)] derived from plasma concentration</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite ratio determined using AUC0-inf for metabolite/AUC0-inf [MRAUC(0-inf)] derived from plasma concentration</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL) derived from plasma concentration</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance (CLR) derived from urine concentration</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events (AE)</measure>
    <time_frame>Up to 31 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events (SAE)</measure>
    <time_frame>Up to 31 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>Up to 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Up to 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC up to time t, where t is the last time point with concentrations above the lower limit of quantitation (AUCt)</measure>
    <time_frame>Up to 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination phase rate constant (λz)</measure>
    <time_frame>Up to 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution during terminal phase (Vz)</measure>
    <time_frame>Up to 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of administered drug excreted into urine (Fe)</measure>
    <time_frame>Up to 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount excreted from time 0 to the time of the last quantifiable sample (Aelast)</measure>
    <time_frame>Up to 36 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Myocardial Failure</condition>
  <condition>Cardiac Failure</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Kidney Failure</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild renal impairment defined as eGFR 60 to &lt;90 mL/min/1.73 m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate renal impairment defined as eGFR 30 to &lt;60 mL/min/1.73 m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe renal impairment defined as eGFR &lt;30 mL/min/1.73 m^2, not requiring dialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal renal function defined as eGFR ≥90 mL/min/1.73 m^2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986231</intervention_name>
    <description>Intravenous infusion administration</description>
    <arm_group_label>Mild Renal Impairment</arm_group_label>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <arm_group_label>Normal renal function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Body weight ≥ 45 kg and ≤ 120 kg

          -  BMI ≥ 18 kg/m^2 and ≤ 35 kg/m^2

          -  Heart rate ≥ 50 bpm and &lt; 95 bpm

          -  Stable renal impairment, defined as no clinically significant change in disease
             status, as documented by the subject's most recent eGFR assessment

          -  No changes in medication within 30 days prior to study drug administration

        Exclusion Criteria:

          -  Clinically relevant abnormal medical history, abnormal findings on physical
             examination, vital signs, ECG, or laboratory tests

          -  History of chronic headaches, defined as occurring 15 days or more a month, over the
             previous 3 months

          -  History of headaches related to caffeine withdrawal

          -  History of migraine or cluster headaches

          -  Patients requiring dialysis will not be enrolled in this study

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Praha 7</city>
        <zip>170 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Krakow</city>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wolomin</city>
        <zip>05-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

